Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for ANGLE plc
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
4
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
27Sep21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Parsortix demonstrates ability to isolate CTCs
22Sep21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Study shows use of Parsortix to assess PD-L1
20Sep21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Parsortix enables gene expression analysis in mPCa
07Sep21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Notice of Interim Results and Webcast
24Aug21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Director/PDMR Shareholding
09Aug21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Study highlights superior performance of Parsortix
06Aug21 13:17
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Issue of Equity
03Aug21 15:13
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Issue of Equity
28Jul21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Contract secured for bespoke assay development
09Jul21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Harvesting CTCs from brain metastasis patients
07Jul21 18:34
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Director/PDMR Shareholding
02Jul21 10:45
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Issue of Equity
30Jun21 15:44
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Result of AGM
25Jun21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Result of Accelerated Bookbuild
24Jun21 18:28
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Accelerated bookbuild to raise up to £20m
18Jun21 11:42
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Annual General Meeting update
18Jun21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - ctDNA and CTCs have differences in EGFR mutations
04Jun21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Update on submission for FDA clearance
01Jun21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Potential to prevent breast cancer relapse
20May21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Parsortix demonstrates oesophageal cancer utility
19May21 16:37
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Angle PLC - Exercise of options and total voting rights
11May21 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix study uncovers targets in TNBC patients
30Apr21 11:22
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Exercise of options and total voting rights
29Apr21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Preliminary Results
26Apr21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Ovarian cancer study patient enrolment completed
16Apr21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
First large-scale pharma services contract secured
15Apr21 16:10
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notice of Preliminary Results and Webcast
12Apr21 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
ANGLE's Parsortix system showcased at AACR 2021
30Mar21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Global launch of clinical services laboratories
04Mar21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Update on submission for FDA clearance
18Feb21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix-harvested CTCs uncover novel biomarker
08Feb21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix: Dynamic assessment of patient response
26Jan21 13:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
20Jan21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Research confirms high performance of Parsortix
12Jan21 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Change of Auditor
05Jan21 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Issue of Equity
09Dec20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix can capture single cancer cell in sample
20Nov20 16:18
RNS
AGL:LON, JUP:LON
ANGLE plc, Jupiter Fund Management plc
Various
Various
Holding(s) in Company
18Nov20 16:51
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
13Nov20 10:46
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Result of General Meeting
03Nov20 14:54
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Director/PDMR Shareholding
29Oct20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Interim Results
27Oct20 18:28
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Result of Placing & Notice of General Meeting
27Oct20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Accelerated bookbuild to raise up to £20m
20Oct20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Submission accepted by FDA for substantive review
28Sep20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Issue of LTIP Options and Share Options
28Sep20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
ANGLE announces completion of FDA submission
23Sep20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Potential treatment strategy to limit metastasis
11Sep20 15:35
RNS
LGEN:LON, AGL:LON
ANGLE plc, Legal & General Group Plc
Various
Various
Holding(s) in Company
11Sep20 15:30
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
02Sep20 13:49
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notification of Interim Results and Webcast
02Sep20 10:00
RNS
AGL:LON, JUP:LON
ANGLE plc, Jupiter Fund Management plc
Various
Various
Holding(s) in Company
27Aug20 15:13
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Result of 2020 Annual General Meeting
18Aug20 09:30
RNS
AGL:LON, JUP:LON
ANGLE plc, Jupiter Fund Management plc
Various
Various
Holding(s) in Company
14Aug20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix use to assess response to immunotherapy
06Aug20 12:20
RNS
AGL:LON, JUP:LON
ANGLE plc, Jupiter Fund Management plc
Various
Various
Holding(s) in Company
05Aug20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notice of AGM and Posting of Annual Report
20Jul20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Study: Parsortix use in metastatic breast cancer
08Jul20 17:35
RNS
AGL:LON, JUP:LON
ANGLE plc, Jupiter Fund Management plc
Various
Various
Holding(s) in Company
08Jul20 17:30
RNS
AGL:LON, JUP:LON
ANGLE plc, Jupiter Fund Management plc
Various
Various
Holding(s) in Company
08Jul20 17:30
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
25Jun20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Preliminary Results
22Jun20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Blood donations recommenced for FDA studies
29May20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notice of Results
12May20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
CTC potential as biomarker in MET inhibitor trials
04May20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Leading cancer centre publishes Parsortix workflow
28Apr20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Business Update
17Apr20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix performance in head and neck cancer
31Mar20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
COVID-19 BUSINESS IMPACT UPDATE
03Mar20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Assessing risk of brain metastasis in lung cancer
27Feb20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix outperforms other CTC systems in RCC
25Feb20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
ANGLE announce Tri-Con presentation with BioView
17Feb20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Data demonstrates key advantages of Parsortix
11Feb20 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Study demonstrates Parsortix potential in melanoma
03Feb20 09:10
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Issue of Equity
30Jan20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Interim Results
30Jan20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Change of accounting reference date
22Jan20 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Successful face-to-face meeting with FDA
08Jan20 12:33
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notice of Results
23Dec19 09:55
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Issue of Equity
07Nov19 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Cancer centre shows Parsortix use in melanoma
30Oct19 14:44
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Result of AGM
30Oct19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Q-submission to FDA containing headline data
08Oct19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notice of AGM
04Oct19 17:54
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
04Oct19 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
European patent granted for megakaryocyte analysis
13Sep19 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Use of Parsortix in head and neck cancer
10Sep19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Research with Parsortix in prostate cancer
04Sep19 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Initiation of Ovarian Cancer Study
31Jul19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Prelim Results for the year ended 30 April 2019
22Jul19 07:00
RNS-R
AGL:LON
ANGLE plc
Health
£31.9m
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
12Jul19 10:22
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Result of General Meeting anf Total Voting Rights
28Jun19 13:37
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Notice of Preliminary Results and Webcast
28Jun19 13:08
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Holding(s) in Company
25Jun19 17:19
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Result of Placing
25Jun19 08:02
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Accelerated bookbuild to raise £18.0m
21Jun19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Parsortix used to investigate immunotherapy target
05Jun19 07:00
RNS
AGL:LON
ANGLE plc
Health
£31.9m
Completion of Ovarian Cancer Pre-Study
«
1
2
3
4
»
Date / Time
Source
Company
% Chg
27Sep21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Parsortix demonstrates ability to isolate CTCs
22Sep21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Study shows use of Parsortix to assess PD-L1
20Sep21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Parsortix enables gene expression analysis in mPCa
07Sep21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Notice of Interim Results and Webcast
24Aug21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Director/PDMR Shareholding
09Aug21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Study highlights superior performance of Parsortix
06Aug21 13:17
RNS
ANGLE plc
-2.00%
Angle PLC - Issue of Equity
03Aug21 15:13
RNS
ANGLE plc
-2.00%
Angle PLC - Issue of Equity
28Jul21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Contract secured for bespoke assay development
09Jul21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Harvesting CTCs from brain metastasis patients
07Jul21 18:34
RNS
ANGLE plc
-2.00%
Angle PLC - Director/PDMR Shareholding
02Jul21 10:45
RNS
ANGLE plc
-2.00%
Angle PLC - Issue of Equity
30Jun21 15:44
RNS
ANGLE plc
-2.00%
Angle PLC - Result of AGM
25Jun21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Result of Accelerated Bookbuild
24Jun21 18:28
RNS
ANGLE plc
-2.00%
Angle PLC - Accelerated bookbuild to raise up to £20m
18Jun21 11:42
RNS
ANGLE plc
-2.00%
Angle PLC - Annual General Meeting update
18Jun21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - ctDNA and CTCs have differences in EGFR mutations
04Jun21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Update on submission for FDA clearance
01Jun21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Potential to prevent breast cancer relapse
20May21 07:00
RNS
ANGLE plc
-2.00%
Angle PLC - Parsortix demonstrates oesophageal cancer utility
19May21 16:37
RNS
ANGLE plc
-2.00%
Angle PLC - Exercise of options and total voting rights
11May21 07:00
RNS-R
ANGLE plc
-2.00%
Parsortix study uncovers targets in TNBC patients
30Apr21 11:22
RNS
ANGLE plc
-2.00%
Exercise of options and total voting rights
29Apr21 07:00
RNS
ANGLE plc
-2.00%
Preliminary Results
26Apr21 07:00
RNS
ANGLE plc
-2.00%
Ovarian cancer study patient enrolment completed
16Apr21 07:00
RNS
ANGLE plc
-2.00%
First large-scale pharma services contract secured
15Apr21 16:10
RNS
ANGLE plc
-2.00%
Notice of Preliminary Results and Webcast
12Apr21 07:00
RNS-R
ANGLE plc
-2.00%
ANGLE's Parsortix system showcased at AACR 2021
30Mar21 07:00
RNS
ANGLE plc
-2.00%
Global launch of clinical services laboratories
04Mar21 07:00
RNS
ANGLE plc
-2.00%
Update on submission for FDA clearance
18Feb21 07:00
RNS
ANGLE plc
-2.00%
Parsortix-harvested CTCs uncover novel biomarker
08Feb21 07:00
RNS
ANGLE plc
-2.00%
Parsortix: Dynamic assessment of patient response
26Jan21 13:00
RNS
ANGLE plc
-2.00%
Holding(s) in Company
20Jan21 07:00
RNS
ANGLE plc
-2.00%
Research confirms high performance of Parsortix
12Jan21 07:00
RNS-R
ANGLE plc
-2.00%
Change of Auditor
05Jan21 07:00
RNS
ANGLE plc
-2.00%
Issue of Equity
09Dec20 07:00
RNS-R
ANGLE plc
-2.00%
Parsortix can capture single cancer cell in sample
20Nov20 16:18
RNS
ANGLE plc, Jupiter Fund Management plc
-2.00%
Holding(s) in Company
18Nov20 16:51
RNS
ANGLE plc
-2.00%
Holding(s) in Company
13Nov20 10:46
RNS
ANGLE plc
-2.00%
Result of General Meeting
03Nov20 14:54
RNS
ANGLE plc
-2.00%
Director/PDMR Shareholding
29Oct20 07:00
RNS
ANGLE plc
-2.00%
Interim Results
27Oct20 18:28
RNS
ANGLE plc
-2.00%
Result of Placing & Notice of General Meeting
27Oct20 07:00
RNS
ANGLE plc
-2.00%
Accelerated bookbuild to raise up to £20m
20Oct20 07:00
RNS-R
ANGLE plc
-2.00%
Submission accepted by FDA for substantive review
28Sep20 07:00
RNS
ANGLE plc
-2.00%
Issue of LTIP Options and Share Options
28Sep20 07:00
RNS
ANGLE plc
-2.00%
ANGLE announces completion of FDA submission
23Sep20 07:00
RNS
ANGLE plc
-2.00%
Potential treatment strategy to limit metastasis
11Sep20 15:35
RNS
ANGLE plc, Legal & General Group Plc
-0.16%
Holding(s) in Company
11Sep20 15:30
RNS
ANGLE plc
-2.00%
Holding(s) in Company
02Sep20 13:49
RNS
ANGLE plc
-2.00%
Notification of Interim Results and Webcast
02Sep20 10:00
RNS
ANGLE plc, Jupiter Fund Management plc
-2.00%
Holding(s) in Company
27Aug20 15:13
RNS
ANGLE plc
-2.00%
Result of 2020 Annual General Meeting
18Aug20 09:30
RNS
ANGLE plc, Jupiter Fund Management plc
-2.00%
Holding(s) in Company
14Aug20 07:00
RNS
ANGLE plc
-2.00%
Parsortix use to assess response to immunotherapy
06Aug20 12:20
RNS
ANGLE plc, Jupiter Fund Management plc
-2.00%
Holding(s) in Company
05Aug20 07:00
RNS
ANGLE plc
-2.00%
Notice of AGM and Posting of Annual Report
20Jul20 07:00
RNS
ANGLE plc
-2.00%
Study: Parsortix use in metastatic breast cancer
08Jul20 17:35
RNS
ANGLE plc, Jupiter Fund Management plc
-2.00%
Holding(s) in Company
08Jul20 17:30
RNS
ANGLE plc, Jupiter Fund Management plc
-2.00%
Holding(s) in Company
08Jul20 17:30
RNS
ANGLE plc
-2.00%
Holding(s) in Company
25Jun20 07:00
RNS
ANGLE plc
-2.00%
Preliminary Results
22Jun20 07:00
RNS
ANGLE plc
-2.00%
Blood donations recommenced for FDA studies
29May20 07:00
RNS
ANGLE plc
-2.00%
Notice of Results
12May20 07:00
RNS-R
ANGLE plc
-2.00%
CTC potential as biomarker in MET inhibitor trials
04May20 07:00
RNS-R
ANGLE plc
-2.00%
Leading cancer centre publishes Parsortix workflow
28Apr20 07:00
RNS
ANGLE plc
-2.00%
Business Update
17Apr20 07:00
RNS
ANGLE plc
-2.00%
Parsortix performance in head and neck cancer
31Mar20 07:00
RNS
ANGLE plc
-2.00%
COVID-19 BUSINESS IMPACT UPDATE
03Mar20 07:00
RNS
ANGLE plc
-2.00%
Assessing risk of brain metastasis in lung cancer
27Feb20 07:00
RNS-R
ANGLE plc
-2.00%
Parsortix outperforms other CTC systems in RCC
25Feb20 07:00
RNS-R
ANGLE plc
-2.00%
ANGLE announce Tri-Con presentation with BioView
17Feb20 07:00
RNS
ANGLE plc
-2.00%
Data demonstrates key advantages of Parsortix
11Feb20 07:00
RNS-R
ANGLE plc
-2.00%
Study demonstrates Parsortix potential in melanoma
03Feb20 09:10
RNS
ANGLE plc
-2.00%
Issue of Equity
30Jan20 07:00
RNS
ANGLE plc
-2.00%
Interim Results
30Jan20 07:00
RNS
ANGLE plc
-2.00%
Change of accounting reference date
22Jan20 07:00
RNS
ANGLE plc
-2.00%
Successful face-to-face meeting with FDA
08Jan20 12:33
RNS
ANGLE plc
-2.00%
Notice of Results
23Dec19 09:55
RNS
ANGLE plc
-2.00%
Issue of Equity
07Nov19 07:00
RNS-R
ANGLE plc
-2.00%
Cancer centre shows Parsortix use in melanoma
30Oct19 14:44
RNS
ANGLE plc
-2.00%
Result of AGM
30Oct19 07:00
RNS
ANGLE plc
-2.00%
Q-submission to FDA containing headline data
08Oct19 07:00
RNS
ANGLE plc
-2.00%
Notice of AGM
04Oct19 17:54
RNS
ANGLE plc
-2.00%
Holding(s) in Company
04Oct19 07:00
RNS-R
ANGLE plc
-2.00%
European patent granted for megakaryocyte analysis
13Sep19 07:00
RNS-R
ANGLE plc
-2.00%
Use of Parsortix in head and neck cancer
10Sep19 07:00
RNS
ANGLE plc
-2.00%
Research with Parsortix in prostate cancer
04Sep19 07:00
RNS-R
ANGLE plc
-2.00%
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00
RNS
ANGLE plc
-2.00%
Initiation of Ovarian Cancer Study
31Jul19 07:00
RNS
ANGLE plc
-2.00%
Prelim Results for the year ended 30 April 2019
22Jul19 07:00
RNS-R
ANGLE plc
-2.00%
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19
RNS
ANGLE plc
-2.00%
Holding(s) in Company
12Jul19 10:22
RNS
ANGLE plc
-2.00%
Result of General Meeting anf Total Voting Rights
28Jun19 13:37
RNS
ANGLE plc
-2.00%
Notice of Preliminary Results and Webcast
28Jun19 13:08
RNS
ANGLE plc
-2.00%
Holding(s) in Company
25Jun19 17:19
RNS
ANGLE plc
-2.00%
Result of Placing
25Jun19 08:02
RNS
ANGLE plc
-2.00%
Accelerated bookbuild to raise £18.0m
21Jun19 07:00
RNS
ANGLE plc
-2.00%
Parsortix used to investigate immunotherapy target
05Jun19 07:00
RNS
ANGLE plc
-2.00%
Completion of Ovarian Cancer Pre-Study
«
1
2
3
4
»
Date / Time
Company
% Chg
27Sep21 07:00
ANGLE plc
-2.00%
Angle PLC - Parsortix demonstrates ability to isolate CTCs
22Sep21 07:00
ANGLE plc
-2.00%
Angle PLC - Study shows use of Parsortix to assess PD-L1
20Sep21 07:00
ANGLE plc
-2.00%
Angle PLC - Parsortix enables gene expression analysis in mPCa
07Sep21 07:00
ANGLE plc
-2.00%
Angle PLC - Notice of Interim Results and Webcast
24Aug21 07:00
ANGLE plc
-2.00%
Angle PLC - Director/PDMR Shareholding
09Aug21 07:00
ANGLE plc
-2.00%
Angle PLC - Study highlights superior performance of Parsortix
06Aug21 13:17
ANGLE plc
-2.00%
Angle PLC - Issue of Equity
03Aug21 15:13
ANGLE plc
-2.00%
Angle PLC - Issue of Equity
28Jul21 07:00
ANGLE plc
-2.00%
Angle PLC - Contract secured for bespoke assay development
09Jul21 07:00
ANGLE plc
-2.00%
Angle PLC - Harvesting CTCs from brain metastasis patients
07Jul21 18:34
ANGLE plc
-2.00%
Angle PLC - Director/PDMR Shareholding
02Jul21 10:45
ANGLE plc
-2.00%
Angle PLC - Issue of Equity
30Jun21 15:44
ANGLE plc
-2.00%
Angle PLC - Result of AGM
25Jun21 07:00
ANGLE plc
-2.00%
Angle PLC - Result of Accelerated Bookbuild
24Jun21 18:28
ANGLE plc
-2.00%
Angle PLC - Accelerated bookbuild to raise up to £20m
18Jun21 11:42
ANGLE plc
-2.00%
Angle PLC - Annual General Meeting update
18Jun21 07:00
ANGLE plc
-2.00%
Angle PLC - ctDNA and CTCs have differences in EGFR mutations
04Jun21 07:00
ANGLE plc
-2.00%
Angle PLC - Update on submission for FDA clearance
01Jun21 07:00
ANGLE plc
-2.00%
Angle PLC - Potential to prevent breast cancer relapse
20May21 07:00
ANGLE plc
-2.00%
Angle PLC - Parsortix demonstrates oesophageal cancer utility
19May21 16:37
ANGLE plc
-2.00%
Angle PLC - Exercise of options and total voting rights
11May21 07:00
ANGLE plc
-2.00%
Parsortix study uncovers targets in TNBC patients
30Apr21 11:22
ANGLE plc
-2.00%
Exercise of options and total voting rights
29Apr21 07:00
ANGLE plc
-2.00%
Preliminary Results
26Apr21 07:00
ANGLE plc
-2.00%
Ovarian cancer study patient enrolment completed
16Apr21 07:00
ANGLE plc
-2.00%
First large-scale pharma services contract secured
15Apr21 16:10
ANGLE plc
-2.00%
Notice of Preliminary Results and Webcast
12Apr21 07:00
ANGLE plc
-2.00%
ANGLE's Parsortix system showcased at AACR 2021
30Mar21 07:00
ANGLE plc
-2.00%
Global launch of clinical services laboratories
04Mar21 07:00
ANGLE plc
-2.00%
Update on submission for FDA clearance
18Feb21 07:00
ANGLE plc
-2.00%
Parsortix-harvested CTCs uncover novel biomarker
08Feb21 07:00
ANGLE plc
-2.00%
Parsortix: Dynamic assessment of patient response
26Jan21 13:00
ANGLE plc
-2.00%
Holding(s) in Company
20Jan21 07:00
ANGLE plc
-2.00%
Research confirms high performance of Parsortix
12Jan21 07:00
ANGLE plc
-2.00%
Change of Auditor
05Jan21 07:00
ANGLE plc
-2.00%
Issue of Equity
09Dec20 07:00
ANGLE plc
-2.00%
Parsortix can capture single cancer cell in sample
20Nov20 16:18
AGL LSE,JUP LSE
-2.00%
Holding(s) in Company
18Nov20 16:51
ANGLE plc
-2.00%
Holding(s) in Company
13Nov20 10:46
ANGLE plc
-2.00%
Result of General Meeting
03Nov20 14:54
ANGLE plc
-2.00%
Director/PDMR Shareholding
29Oct20 07:00
ANGLE plc
-2.00%
Interim Results
27Oct20 18:28
ANGLE plc
-2.00%
Result of Placing & Notice of General Meeting
27Oct20 07:00
ANGLE plc
-2.00%
Accelerated bookbuild to raise up to £20m
20Oct20 07:00
ANGLE plc
-2.00%
Submission accepted by FDA for substantive review
28Sep20 07:00
ANGLE plc
-2.00%
Issue of LTIP Options and Share Options
28Sep20 07:00
ANGLE plc
-2.00%
ANGLE announces completion of FDA submission
23Sep20 07:00
ANGLE plc
-2.00%
Potential treatment strategy to limit metastasis
11Sep20 15:35
AGL LSE,LGEN LSE
-0.16%
Holding(s) in Company
11Sep20 15:30
ANGLE plc
-2.00%
Holding(s) in Company
02Sep20 13:49
ANGLE plc
-2.00%
Notification of Interim Results and Webcast
02Sep20 10:00
AGL LSE,JUP LSE
-2.00%
Holding(s) in Company
27Aug20 15:13
ANGLE plc
-2.00%
Result of 2020 Annual General Meeting
18Aug20 09:30
AGL LSE,JUP LSE
-2.00%
Holding(s) in Company
14Aug20 07:00
ANGLE plc
-2.00%
Parsortix use to assess response to immunotherapy
06Aug20 12:20
AGL LSE,JUP LSE
-2.00%
Holding(s) in Company
05Aug20 07:00
ANGLE plc
-2.00%
Notice of AGM and Posting of Annual Report
20Jul20 07:00
ANGLE plc
-2.00%
Study: Parsortix use in metastatic breast cancer
08Jul20 17:35
AGL LSE,JUP LSE
-2.00%
Holding(s) in Company
08Jul20 17:30
AGL LSE,JUP LSE
-2.00%
Holding(s) in Company
08Jul20 17:30
ANGLE plc
-2.00%
Holding(s) in Company
25Jun20 07:00
ANGLE plc
-2.00%
Preliminary Results
22Jun20 07:00
ANGLE plc
-2.00%
Blood donations recommenced for FDA studies
29May20 07:00
ANGLE plc
-2.00%
Notice of Results
12May20 07:00
ANGLE plc
-2.00%
CTC potential as biomarker in MET inhibitor trials
04May20 07:00
ANGLE plc
-2.00%
Leading cancer centre publishes Parsortix workflow
28Apr20 07:00
ANGLE plc
-2.00%
Business Update
17Apr20 07:00
ANGLE plc
-2.00%
Parsortix performance in head and neck cancer
31Mar20 07:00
ANGLE plc
-2.00%
COVID-19 BUSINESS IMPACT UPDATE
03Mar20 07:00
ANGLE plc
-2.00%
Assessing risk of brain metastasis in lung cancer
27Feb20 07:00
ANGLE plc
-2.00%
Parsortix outperforms other CTC systems in RCC
25Feb20 07:00
ANGLE plc
-2.00%
ANGLE announce Tri-Con presentation with BioView
17Feb20 07:00
ANGLE plc
-2.00%
Data demonstrates key advantages of Parsortix
11Feb20 07:00
ANGLE plc
-2.00%
Study demonstrates Parsortix potential in melanoma
03Feb20 09:10
ANGLE plc
-2.00%
Issue of Equity
30Jan20 07:00
ANGLE plc
-2.00%
Interim Results
30Jan20 07:00
ANGLE plc
-2.00%
Change of accounting reference date
22Jan20 07:00
ANGLE plc
-2.00%
Successful face-to-face meeting with FDA
08Jan20 12:33
ANGLE plc
-2.00%
Notice of Results
23Dec19 09:55
ANGLE plc
-2.00%
Issue of Equity
07Nov19 07:00
ANGLE plc
-2.00%
Cancer centre shows Parsortix use in melanoma
30Oct19 14:44
ANGLE plc
-2.00%
Result of AGM
30Oct19 07:00
ANGLE plc
-2.00%
Q-submission to FDA containing headline data
08Oct19 07:00
ANGLE plc
-2.00%
Notice of AGM
04Oct19 17:54
ANGLE plc
-2.00%
Holding(s) in Company
04Oct19 07:00
ANGLE plc
-2.00%
European patent granted for megakaryocyte analysis
13Sep19 07:00
ANGLE plc
-2.00%
Use of Parsortix in head and neck cancer
10Sep19 07:00
ANGLE plc
-2.00%
Research with Parsortix in prostate cancer
04Sep19 07:00
ANGLE plc
-2.00%
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00
ANGLE plc
-2.00%
Initiation of Ovarian Cancer Study
31Jul19 07:00
ANGLE plc
-2.00%
Prelim Results for the year ended 30 April 2019
22Jul19 07:00
ANGLE plc
-2.00%
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19
ANGLE plc
-2.00%
Holding(s) in Company
12Jul19 10:22
ANGLE plc
-2.00%
Result of General Meeting anf Total Voting Rights
28Jun19 13:37
ANGLE plc
-2.00%
Notice of Preliminary Results and Webcast
28Jun19 13:08
ANGLE plc
-2.00%
Holding(s) in Company
25Jun19 17:19
ANGLE plc
-2.00%
Result of Placing
25Jun19 08:02
ANGLE plc
-2.00%
Accelerated bookbuild to raise £18.0m
21Jun19 07:00
ANGLE plc
-2.00%
Parsortix used to investigate immunotherapy target
05Jun19 07:00
ANGLE plc
-2.00%
Completion of Ovarian Cancer Pre-Study
«
1
2
3
4
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: